Akeso
Manufacturing · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
No. 6 Shennong Road Torch Development Zo...Phone Number
+86 76089873998Website
www.akesobio.comRevenue
$626.5 MillionStock Symbol
9926Industry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Akeso
Akeso, Inc is a pioneering biopharmaceutical company focused on the research and development of innovative antibody drugs for major diseases such as cancer, autoimmune disorders, and metabolic diseases. The company has developed a unique end-to-end drug research and development platform known as the ACE Platform, which incorporates advanced technologies like Tetrabody and Dual-Shield ADCT. With a commitment to addressing unmet clinical needs globally, Akeso aims to provide affordable innovative antibody drug solutions while creating significant commercial and social value. The company actively seeks strategic partnerships for collaborative product development and licensing both in China and internationally.Explore more
Akeso Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Akeso your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Akeso launches new products
Funding: Get notified immidiatlly once Akeso has new funding data
Check if Akeso has recently received funding, and reach out quickly before it becomes old news!
Click to see if Akeso had a recent Job posting/layoffs
Akeso, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Akeso recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Akeso
Check out if Akeso is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Akeso is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Akeso is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Akeso.
Akeso financials insights
Gather financial insights about Akeso, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$19.5M
2017
Series B
$2.7M
2019
Series D
$150M
2024
Share Placement
$250M
Akeso Tech Stack
A closer look at the technologies used by Akeso
Most Recent Scoops
Project
Product Management, Certifications, Pharmaceuticals
Event
Person-Based
Bing Wang, Chief Financial Officer, appeared on a podcast called "BioCentury This Week" on 11/01/2025. Topics discussed include China Biotech Innovation, Clinical Development, Global Markets.
Events, Podcast
Person-Based
Person-Based
Project
Spending/Investment
Akeso News & Media
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the...Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
HONG KONG, Jan. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory...Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific antibody) was selected for inclusion. It stands asAkeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis
HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). There are approximately 4 million AS patients in China, and gumokimab represents a potentially promising new therapeutic o
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Akeso
Sign Up For FreeTo access detailed company insights
Akeso, Inc is a pioneering biopharmaceutical company focused on the research and development of innovative antibody drugs for major diseases such as cancer, autoimmune disorders, and metabolic diseases. The company has developed a unique end-to-end drug research and development platform known as the ACE Platform, which incorporates advanced technol... Read More
